NeoGenomics
256 hedge funds and large institutions have $2.02B invested in NeoGenomics in 2023 Q1 according to their latest regulatory filings, with 42 funds opening new positions, 72 increasing their positions, 89 reducing their positions, and 25 closing their positions.
400% more funds holding in top 10
Funds holding in top 10: 1 → 5 (+4)
152% more call options, than puts
Call options by funds: $13.4M | Put options by funds: $5.32M
98% more capital invested
Capital invested by funds: $1.02B → $2.02B (+$999M)
68% more first-time investments, than exits
New positions opened: 42 | Existing positions closed: 25
6% more funds holding
Funds holding: 242 → 256 (+14)
3.41% more ownership
Funds ownership: 87.72% → 91.13% (+3.4%)
19% less repeat investments, than reductions
Existing positions increased: 72 | Existing positions reduced: 89
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$28.3M |
| 2 |
Janus Henderson Group
London,
|
+$18.5M |
| 3 |
Invesco
Atlanta,
Georgia
|
+$18.1M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$11.7M |
| 5 |
LCG
Lisanti Capital Growth
New York
|
+$7.53M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$36.6M |
| 2 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$11.3M |
| 3 |
FAM
Fred Alger Management
New York
|
-$10.7M |
| 4 |
BlackRock
New York
|
-$8.9M |
| 5 |
EA
Emerald Advisers
Leola,
Pennsylvania
|
-$6.16M |
NEO Hedge Fund Activity: Q1 2023 in Review
256 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in NeoGenomics (NEO) for Q1 2023, worth a combined $2.02B — up 98% from $1.02B a quarter earlier.
Buyers outnumbered sellers: 42 funds opened new NEO positions and 25 closed out — a net gain of 17 holders — while 72 added to existing stakes and 89 trimmed.
The largest buyer was T. Rowe Price Investment Management, adding an estimated $28.3M. The largest seller was Millennium Management, cutting an estimated $36.6M.
- 256 institutional investors held NeoGenomics (NEO) as of Q1 2023, up from 242 in Q4 2022.
- Funds reported $2.02B of NeoGenomics stock for Q1 2023, up 98% quarter-over-quarter.
- 42 funds opened new NeoGenomics positions in Q1 2023 and 25 closed out, a net change of +17 holders.
- The largest NeoGenomics buyer in Q1 2023 was T. Rowe Price Investment Management, an estimated $28.3M added.
- The largest NeoGenomics seller in Q1 2023 was Millennium Management, an estimated $36.6M sold.
Based on aggregated 13F filings for Q1 2023.